Analysts delivered a cluster of downgrades over the weekend. Three notable names took hits as the new week began.
Johnson Controls was cut to a lower rating. The building tech giant carries a $89 billion market cap. Its average analyst target price slipped to $162.05, down from $161.05. The consensus now stands at 10 buys, 8 holds, and 2 sells.
Bristol-Myers Squibb also received a downgrade. The $133 billion pharma saw its target price edge to $64.91. Sells outnumber buys 9 to 8 among covering analysts. That ratio flags growing caution on the stock.
Zebra Technologies was the third downgrade. The barcode and enterprise tech firm dropped to 5 buys from a prior 4. Its short interest sits at 6.9% of free float — modest but worth watching.
On the brighter side, Amazon saw a consensus target price lift to $321.95. The e-commerce giant now commands near-unanimous buy support from 59 analysts. AbbVie also got a nudge higher to $270.39 average target.
received a fresh new recommendation. Its consensus target sits at $166.67, with 20 buys on record.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
